

CONTACT - Media:

Amsterdam +31.20.721.4133
Dublin +353 1 617 4221
Oslo +47 22 34 19 15

Brussels +32.2.620.15.50
Lisbon +351.210.600.614
Paris +33.1.70.48.24.45

CONTACT - Investor Relations:

+33.1.70.48.24.17

THE BIOTECH APTORUM GROUP LISTS ON EURONEXT



Paris – 24 July 2020 – Euronext today congratulated Aptorum Group Limited (ticker code: APM on Euronext and Nasdaq), a biopharmaceutical company focusing on the development of novel therapeutics to address unmet medical needs globally, on its listing in the professional compartment of Euronext’s regulated market in Paris. Listed on Nasdaq since 2018, Aptorum is joining Euronext’s strong biotech franchise, which is now composed of 62 companies.

Aptorum Group is a pharmaceutical company dedicated to developing and commercialising novel therapeutics to tackle unmet medical needs. To date, Aptorum Group has a therapeutic development pipeline of over 15 drugs, including indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases in the future. Aptorum Group is also launching a women’s health supplement, dioscorea opposita bioactive nutraceutical tablets, to be marketed under the brand name NativusWell[®].

With presence in multiple locations in North America, Asia and the United Kingdom, Aptorum Group has access to a broad spectrum of research and development capabilities, and human capital. Aptorum Group has also established strong relationships and collaborations with leading academic institutions to propel therapeutic innovations.

Aptorum Group Limited listed through the admission to trading of its 7,950,986 Class A ordinary shares*. The admission price of Aptorum Group Limited was set at around €3.22 per share, being the closing price of APM on 23 July 2020. Market capitalisation of the class A shares was approximately €25.6 million on the day of listing.

During the Euronext IPO ceremony, Darren Lui, President and Executive Director of Aptorum Group said: *“We are proud to list on Euronext Paris, a new important milestone for Aptorum Group, after our successful listing on Nasdaq. Europe is a key market for our future developments. I am confident that the cross-listing, in addition to enhancing the shareholder base, attracting collaborations and raising the company’s global recognition, will also help us in expanding our footprint in Europe and offer us new business opportunities to engage in research and development projects.”*

*the Company’s issued share capital consists of 7,950,986 Class A ordinary shares and 22,437,754 Class B ordinary shares.



Caption: Darren Lui, President and Executive Director of Aptorum Group, and Sebastian Grabert, Business Development Manager Listing of Euronext, rang the bell to celebrate Aptorum's listing.

CONTACTS APTORUM

Tel: +852 3953 7700

investor.relations@aptorumgroup.com

Actifin – Financial Communications Europe
+33 1 56 88 11 22

Ghislaine Gasparetto - ggasparetto@actifin.fr

Redchip – Financial Communications United States
+1 407 491 4498

dave@redchip.com

CONTACTS EURONEXT

Pauline Bucaille (Europe/Paris) :
Aurélie Cohen (Europe/Paris) :

+33 1 70 48 24 41; pbucaille@euronext.com
+33 1 70 48 24 17; acohen@euronext.com

About Aptorum Group

Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company dedicated to developing and commercialising novel therapeutics to tackle unmet medical needs. Aptorum Group's current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases. Aptorum Group is also launching a women's health supplement, dioscorea opposita bioactive nutraceutical tablets marketed under the brand name NativusWell®. For more information about the Company, please visit our website: www.aptorumgroup.com.

About Euronext

Euronext is the leading pan-European market infrastructure, connecting local economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, The Netherlands, Norway and Portugal. With close to 1,500 listed issuers worth €3.8 trillion in market capitalisation as of end June 2020, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates Euronext Growth™ and Euronext Acces™, simplifying access to listing for SMEs. Euronext provides custody and settlement services through central securities depositories in Denmark, Norway and Portugal. For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer

This press release is for information purposes only; it is not a recommendation to engage in investment activities and is provided “as is”, without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Actual results may differ materially from projections included in this press release. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.
© 2020, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, “GDPR”), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: www.euronext.com/privacy-policy.

In accordance with the applicable legislation you have rights with regard to the processing of your personal data:

- for more information on your rights, please refer to: www.euronext.com/data_subjects_rights_request_information,
- to make a request regarding processing of your data or to unsubscribe to this press release service, please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at dpo@euronext.com.